Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Hua Medicine and Roche have signed a licensing agreement for Roche's Glucokinase Activator (GKA) program.
Subscribe to our email newsletter
As per the agreement, Hua will receive the full preclinical and clinical documentation for Roche’s GKA program, drug product API for RO5305552, and rights to potential back-up compounds.
Roche will receive an upfront payment, milestones and royalty. Hua has received development, manufacturing, and worldwide sales and marketing rights with the rights to sub-license.
GKA is a small molecule activator of the glucokinase enzyme which plays a key role in regulating carbohydrate metabolism.
By increasing this enzyme’s activity, GKA has the therapeutic potential to help lower elevated blood glucose levels seen in diabetes.
Hua CEO Li Chen said Roche’s GKA was designed to be a best-in-class drug candidate based on their extensive preclinical, clinical, and mechanistic experience with GK activation.